Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment options experienced significant quality of life (QoL) improvements after undergoing transcatheter arterialization of the deep veins (TADV).
This article was originally published on MedicalXpress.com

